Clinic
Saint Elizabeth Regional Medical Center
Saint Elizabeth Regional Medical Center was paid $14.93M by Medicaid between Jan 2018 and Dec 2024, across 220 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoSAINT ELIZABETH REGIONAL MEDICAL CENTER
LINCOLN, NE 68510
LINCOLN, NE 68510
33aNPI1336155738assigned 07/31/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$14.93M
24GClaims424,131
24DCodes billed220
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Nebraska
Rank by total paid#3 of 35
Median peer was paid$190K
This provider vs. median78×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KUIPER, EVERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,276 | $1.82M | |
| 2019 | 46,113 | $1.84M | |
| 2020 | 52,324 | $1.90M | |
| 2021 | 97,592 | $2.70M | |
| 2022 | 102,622 | $3.19M | |
| 2023 | 53,721 | $2.11M | |
| 2024incomplete | 24,483 | $1.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 24,444 | 22,632 | $3.59M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 18,666 | 16,390 | $2.63M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.1% | 4,105 | 2,947 | $909K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.1% | 2,305 | 2,033 | $763K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.9% | 4,685 | 4,039 | $724K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.4% | 5,465 | 5,078 | $659K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 2,145 | 1,940 | $488K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.9% | 3,250 | 2,177 | $436K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 3,460 | 3,295 | $295K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 2,575 | 1,746 | $259K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 794 | 736 | $243K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 2,946 | 2,841 | $239K |
208 more codes
| 59050 | 1.6% | 1,069 | $234K | |
| G0378 | Hospital observation service, per hour | 1.3% | 1,921 | $193K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 956 | $177K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 2,259 | $172K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,756 | $113K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 552 | $101K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,014 | $100K |
| 80053 | Comprehensive metabolic panel | <1% | 16,605 | $93K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,925 | $92K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 124 | $86K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,684 | $86K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 442 | $83K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 658 | $80K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,598 | $80K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 970 | $80K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,675 | $75K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 311 | $73K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,335 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,716 | $70K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 2,328 | $69K |
| J3490 | Unclassified drugs | <1% | 28,870 | $67K |
| 80050 | General health panel | <1% | 6,714 | $59K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,826 | $58K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,338 | $52K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 383 | $48K |
| 84439 | <1% | 3,278 | $44K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,774 | $42K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 320 | $40K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,416 | $38K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,726 | $35K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 622 | $34K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,631 | $34K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,785 | $33K |
| 16020 | <1% | 473 | $32K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,704 | $31K |
| 96376 | <1% | 2,461 | $30K | |
| 80061 | Lipid panel | <1% | 5,181 | $29K |
| 93971 | <1% | 181 | $26K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,580 | $25K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,066 | $25K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 582 | $23K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,353 | $23K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 634 | $23K |
| 85027 | <1% | 4,247 | $21K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 92 | $21K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,039 | $21K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,019 | $21K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,992 | $19K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 42 | $17K |
| 86140 | <1% | 2,967 | $17K | |
| 74018 | <1% | 709 | $16K | |
| 87081 | <1% | 2,290 | $16K | |
| 76830 | Ultrasound, transvaginal | <1% | 277 | $15K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,677 | $15K |
| G0422 | Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session | <1% | 238 | $14K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,850 | $14K |
| 84484 | <1% | 6,155 | $14K | |
| 97116 | <1% | 540 | $13K | |
| 84702 | <1% | 1,154 | $12K | |
| 87480 | <1% | 1,593 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,011 | $11K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 47 | $11K |
| 84703 | <1% | 3,747 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,310 | $11K |
| 81001 | <1% | 9,979 | $10K | |
| 97165 | <1% | 368 | $10K | |
| 84145 | <1% | 531 | $10K | |
| 83690 | <1% | 5,707 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,561 | $10K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 13,845 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,003 | $9K |
| 83880 | <1% | 980 | $9K | |
| 82607 | <1% | 668 | $9K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 25 | $9K |
| 82728 | <1% | 744 | $8K | |
| 87660 | <1% | 1,593 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,702 | $7K |
| 73610 | <1% | 257 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 112 | $7K |
| 87077 | <1% | 1,468 | $7K | |
| 59025 | Fetal non-stress test | <1% | 29 | $7K |
| 81514 | <1% | 66 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,490 | $7K |
| 81003 | <1% | 4,216 | $7K | |
| 87510 | <1% | 1,593 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 836 | $6K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,406 | $6K |
| 86803 | <1% | 568 | $6K | |
| 83735 | <1% | 2,137 | $6K | |
| 85652 | <1% | 1,625 | $6K | |
| 82962 | <1% | 4,893 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 326 | $6K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 115 | $6K |
| 86850 | <1% | 501 | $5K | |
| 76801 | <1% | 145 | $5K | |
| 87186 | <1% | 1,389 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 114 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 114 | $4K |
| 76536 | <1% | 27 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 30 | $4K |
| 11045 | <1% | 22 | $4K | |
| 73630 | <1% | 131 | $4K | |
| 80081 | <1% | 377 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 41 | $4K |
| 12001 | <1% | 12 | $4K | |
| 87040 | <1% | 873 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,638 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,138 | $4K |
| 86900 | <1% | 635 | $4K | |
| 86480 | <1% | 99 | $4K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 305 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 688 | $4K |
| 97161 | <1% | 336 | $4K | |
| 85610 | <1% | 2,027 | $4K | |
| 83540 | <1% | 712 | $4K | |
| 83605 | <1% | 1,262 | $4K | |
| 70486 | <1% | 41 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 971 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,863 | $3K |
| 85379 | <1% | 1,368 | $3K | |
| 87070 | <1% | 627 | $3K | |
| 76642 | <1% | 17 | $3K | |
| A9270 | Non-covered item or service | <1% | 6,716 | $3K |
| A4217 | Sterile water/saline, 500 ml | <1% | 163 | $2K |
| 82950 | <1% | 421 | $2K | |
| 80076 | <1% | 437 | $2K | |
| 83550 | <1% | 371 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 49 | $2K |
| 87807 | <1% | 121 | $2K | |
| 81025 | <1% | 1,503 | $2K | |
| 72100 | <1% | 44 | $2K | |
| 87210 | <1% | 844 | $2K | |
| 73110 | <1% | 81 | $2K | |
| 85730 | <1% | 628 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 96 | $1K |
| 82043 | <1% | 493 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 784 | $1K |
| 84481 | <1% | 163 | $1K | |
| 94760 | <1% | 1,163 | $1K | |
| 87420 | <1% | 159 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 151 | $1K |
| 87147 | <1% | 399 | $1K | |
| 86780 | <1% | 139 | $1K | |
| 86901 | <1% | 784 | $1K | |
| 84153 | <1% | 124 | $1K | |
| A4649 | Surgical supply; miscellaneous | <1% | 392 | $1K |
| 73030 | <1% | 212 | $1K | |
| 80306 | <1% | 66 | $1K | |
| 83516 | <1% | 83 | $972.12 | |
| 86038 | <1% | 98 | $929.99 | |
| 87205 | <1% | 593 | $892.95 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 125 | $887.37 |
| 84112 | <1% | 28 | $834.75 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 281 | $831.97 |
| 90715 | <1% | 31 | $812.77 | |
| 84100 | <1% | 554 | $806.38 | |
| 96367 | <1% | 60 | $787.58 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,915 | $728.66 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 128 | $702.30 |
| 94761 | <1% | 461 | $652.40 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 55 | $652.21 |
| 51701 | <1% | 27 | $646.07 | |
| 99152 | <1% | 13 | $611.55 | |
| 71250 | <1% | 15 | $569.14 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 82 | $463.32 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 274 | $419.41 |
| 73130 | <1% | 109 | $360.37 | |
| 84403 | <1% | 27 | $342.76 | |
| 83001 | <1% | 27 | $256.22 | |
| 86376 | <1% | 28 | $254.27 | |
| 73560 | <1% | 186 | $244.63 | |
| 82570 | <1% | 94 | $230.31 | |
| 36600 | <1% | 16 | $230.11 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 388 | $224.30 |
| 82670 | <1% | 13 | $205.43 | |
| 94762 | <1% | 17 | $174.34 | |
| 86431 | <1% | 27 | $172.41 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 443 | $164.25 |
| 84270 | <1% | 12 | $153.47 | |
| 82746 | <1% | 14 | $147.78 | |
| 88342 | <1% | 16 | $122.41 | |
| 84146 | <1% | 12 | $122.32 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 15 | $110.00 |
| 87075 | <1% | 38 | $108.93 | |
| 84156 | <1% | 64 | $85.34 | |
| 73502 | <1% | 39 | $62.97 | |
| 88304 | <1% | 17 | $47.73 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 33 | $47.56 |
| J1815 | Injection, insulin, per 5 units | <1% | 32 | $46.04 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 48 | $45.11 |
| 82550 | <1% | 18 | $32.07 | |
| 82270 | <1% | 14 | $24.92 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 222 | $22.89 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 661 | $21.68 |
| 85018 | <1% | 17 | $17.23 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 21 | $16.37 |
| 82803 | <1% | 17 | $14.71 | |
| 82077 | <1% | 691 | $14.57 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 12 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 19 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 18 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 105 | $0.00 |
| 80179 | 0% | 15 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
| 85007 | 0% | 14 | $0.00 | |
| 80143 | 0% | 15 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 178 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 63 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKUIPER, EVERT (CEO - CHI HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.